EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes

Salvatore Crisafulli, Wajd Alkabbani, Julie M Paik, Katsiaryna Bykov iD, Ali Tavakkoli iD, Robert J Glynn, Phyo T Htoo iD, Elaine W Yu, Gianluca Trifirò iD, Deborah J Wexler iD, Elisabetta Patorno

Annals of Internal Medicine · 2026

DOI: 10.7326/annals-25-01724 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Salvatore Crisafulli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Recombinant Fusion Proteins, Hypoglycemic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAMS NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The comparative gastrointestinal safety across glucagon-like peptide-1 receptor agonists and tirzepatide is still unclear. OBJECTIVE: To compare the risk for severe gastrointestinal adverse events across dulaglutide, subcutaneous semaglutide, and tirzepatide in patients with type 2 diabetes (T2D) in routine clinical practice. DESIGN: New-user, active-comparator cohort study. SETTING: Population-based study. PARTICIPANTS: Adults with T2D initiating dulaglutide, subcutaneous semaglutide, and tirzepatide between 1 January 2019 and 30 August 2024 in 3 cohorts corresponding to 3 pairwise comparisons. MEASUREMENTS: The primary outcome was a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation. Secondary outcomes of interest were the individual components of the primary outcome. Patients were 1:1 propensity score matched within each comparison. We calculated hazard ratios (HRs) with 95% CIs. RESULTS: There were 65 238 matched pairs in the semaglutide versus dulaglutide cohort, 20 893 in the tirzepatide versus dulaglutide cohort, and 46 620 in the tirzepatide versus semaglutide cohort. The HR of gastrointestinal events was 0.96 (95% CI, 0.87 to 1.06) in the semaglutide versus dulaglutide cohort, 0.96 (CI, 0.77 to 1.20) in the tirzepatide versus dulaglutide cohort, and 1.07 (CI, 0.90 to 1.26) in the tirzepatide versus semaglutide cohort. LIMITATION: Possible residual confounding by glycemic control and body mass index. CONCLUSION: These findings suggest that dulaglutide, semaglutide, and tirzepatide have similar gastrointestinal safety profiles in adults with T2D. This study provides clinicians with evidence to weigh the benefits and risks of these medications. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesDiabetes Mellitus, Type 2Recombinant Fusion ProteinsHypoglycemic AgentsImmunoglobulin Fc FragmentsTirzepatideGastrointestinal DiseasesHumansMaleFemaleMiddle AgedAgedAdultGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

Glucagon-Like PeptidesdulaglutideRecombinant Fusion ProteinsHypoglycemic AgentsImmunoglobulin Fc FragmentsTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and Department of Diagnostics and Public Health, University…
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and School of Pharmacy, University of Waterloo, Waterloo, O…
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's H…
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (K.B., R.J.G., P.T.H., E.P.).
  • Division of General and Gastrointestinal Surgery, Brigham and Women's Hospital, Boston, Massachusetts (A.T.).
  • Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, and Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts (E.W.Y.).

ORCID-Profile: Katsiaryna Bykov, Ali Tavakkoli, Phyo T Htoo, Gianluca Trifirò, Deborah J Wexler

Förderung

  • NIDDK NIH HHS
  • NIAMS NIH HHS
  • FDA HHS
  • NIA NIH HHS

Zitieren

APA

Crisafulli, S., Alkabbani, W., Paik, J. M., Bykov, K., Tavakkoli, A., Glynn, R. J., Htoo, P. T., Yu, E. W., Trifirò, G., Wexler, D. J., & Patorno, E. (2026). Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-01724

Vancouver

Crisafulli S, Alkabbani W, Paik JM, Bykov K, Tavakkoli A, Glynn RJ, et al. Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. Annals of Internal Medicine. 2026. doi:10.7326/annals-25-01724

BibTeX
@article{Crisafulli2026,
  author = {Crisafulli, Salvatore and Alkabbani, Wajd and Paik, Julie M and Bykov, Katsiaryna and Tavakkoli, Ali and Glynn, Robert J and Htoo, Phyo T and Yu, Elaine W and Trifirò, Gianluca and Wexler, Deborah J and Patorno, Elisabetta},
  title = {Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes},
  journal = {Annals of Internal Medicine},
  year = {2026},
  doi = {10.7326/annals-25-01724}
}
Kostenlos starten →